Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Humacyte Inc shares valued at $20,181 were purchased by Constantino Michael T. on Dec 04 ’24. At $4.39 per share, Constantino Michael T. acquired 4,600 shares. The insider’s holdings grew to 16,950 shares worth approximately $58647.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Niklason Laura E purchased 1,797 shares, netting a total of over 7,979 in proceeds. Following the buying of shares at $4.44 each, the insider now holds 243,851 shares.
Before that, Dougan Brady W had added 1,797 shares to its account. In a trade valued at $7,979, the Director bought Humacyte Inc shares for $4.44 each. Upon closing the transaction, the insider’s holdings increased to 1,797 shares, worth approximately $0.84 million.
As published in their initiating research note from H.C. Wainwright on December 11, 2023, Humacyte Inc [HUMA] has been a Buy and the price target has been revised to $6. Analysts at Piper Sandler upgraded the stock from ‘”an Underweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid August. As of June 22, 2023, Cantor Fitzgerald has initiated its “an Overweight” rating for HUMA. Earlier on May 16, 2022, Piper Sandler downgraded its rating. Their new recommendation was “an Underweight” for HUMA stock which previously was a “an Overweight”.
Analyzing HUMA Stock Performance
During the last five days, there has been a drop of approximately -15.20%. Over the course of the year, Humacyte Inc shares have jumped approximately 21.83%. Shares of the company reached a 52-week high of $9.97 on 05/31/24 and a 52-week low of $2.48 on 01/17/24. A 50-day SMA is recorded $4.87, while a 200-day SMA reached $5.42. Nevertheless, trading volume fell to 2.83 million shares from 5.74 million shares the previous day.
Support And Resistance Levels for Humacyte Inc (HUMA)
According to the 24-hour chart, there is a support level at 3.34, which, if violated, would cause prices to drop to 3.21. In the upper region, resistance lies at 3.62. The next price resistance is at 3.78. RSI (Relative Strength Index) is 31.82 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.58, which suggests the price will decrease in the coming days. Percent R is at 94.58%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
